Published On: Tue, Sep 13th, 2016

Insider Buying: Opko Health Inc. (OPK) CEO Acquires 3,600 Shares of Stock

Opko Health Inc. (NYSE:OPK) CEO Phillip Md Et Al Frost acquired 3,600 shares of the firm’s stock in a transaction on Friday, September 9th. The stock was bought at an average price of $9.87 per share, for a total transaction of $35,532.00. Following the completion of the acquisition, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $30,290,546.37. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Phillip Md Et Al Frost also recently made the following trade(s):

On Friday, September 2nd, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The stock was bought at an average price of $9.28 per share, for a total transaction of $92,800.00.
On Thursday, August 25th, Phillip Md Et Al Frost acquired 48,400 shares of Opko Health stock. The stock was bought at an average price of $9.06 per share, for a total transaction of $438,504.00.
On Wednesday, August 24th, Phillip Md Et Al Frost acquired 15,000 shares of Opko Health stock. The stock was bought at an average price of $9.24 per share, for a total transaction of $138,600.00.
On Tuesday, August 23rd, Phillip Md Et Al Frost acquired 29,000 shares of Opko Health stock. The stock was bought at an average price of $9.53 per share, for a total transaction of $276,370.00.
On Monday, August 22nd, Phillip Md Et Al Frost acquired 11,800 shares of Opko Health stock. The stock was bought at an average price of $9.76 per share, for a total transaction of $115,168.00.
On Friday, August 19th, Phillip Md Et Al Frost acquired 15,000 shares of Opko Health stock. The stock was bought at an average price of $9.82 per share, for a total transaction of $147,300.00.
On Thursday, August 18th, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The stock was bought at an average price of $9.87 per share, for a total transaction of $98,700.00.
On Wednesday, August 17th, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The stock was bought at an average price of $9.90 per share, for a total transaction of $99,000.00.
On Tuesday, August 16th, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The stock was bought at an average price of $10.02 per share, for a total transaction of $100,200.00.
On Monday, August 15th, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The stock was bought at an average price of $10.07 per share, for a total transaction of $100,700.00.

Shares of Opko Health Inc. (NYSE:OPK) opened at 9.89 on Tuesday. Opko Health Inc. has a 52-week low of $7.12 and a 52-week high of $11.85. The company has a market cap of $5.44 billion and a PE ratio of 41.38. The company’s 50-day moving average is $9.77 and its 200 day moving average is $10.07.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/13/insider-buying-opko-health-inc-opk-ceo-acquires-3600-shares-of-stock.html

Opko Health (NYSE:OPK) last issued its quarterly earnings data on Monday, August 8th. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.05. The company had revenue of $357.10 million for the quarter, compared to the consensus estimate of $324.11 million. During the same quarter last year, the business posted ($0.09) earnings per share. Opko Health’s revenue was up 742.2% on a year-over-year basis. On average, analysts anticipate that Opko Health Inc. will post ($0.05) EPS for the current year.
A number of institutional investors have recently modified their holdings of OPK. Teachers Advisors Inc. boosted its position in shares of Opko Health by 3.6% in the first quarter. Teachers Advisors Inc. now owns 325,172 shares of the company’s stock valued at $3,379,000 after buying an additional 11,403 shares during the period. Parametrica Management Ltd bought a new position in shares of Opko Health during the first quarter valued at $336,000. Hyman Charles D bought a new position in shares of Opko Health during the first quarter valued at $188,000. Virginia Retirement System bought a new position in shares of Opko Health during the first quarter valued at $510,000. Finally, Aperio Group LLC boosted its position in shares of Opko Health by 67.1% in the first quarter. Aperio Group LLC now owns 63,042 shares of the company’s stock valued at $655,000 after buying an additional 25,312 shares during the period.
A number of equities research analysts have recently issued reports on the stock. Jefferies Group reissued a “hold” rating on shares of Opko Health in a research report on Wednesday, August 17th. JPMorgan Chase & Co. set a $14.00 target price on shares of Opko Health and gave the company a “buy” rating in a research report on Tuesday, August 9th. Deutsche Bank AG reduced their target price on shares of Opko Health from $11.00 to $10.00 and set a “hold” rating for the company in a research report on Thursday, June 16th. Oppenheimer Holdings Inc. reissued an “outperform” rating on shares of Opko Health in a research report on Saturday, June 25th. Finally, Standpoint Research assumed coverage on shares of Opko Health in a research report on Friday, June 3rd. They issued a “buy” rating and a $16.00 target price for the company. Five research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Opko Health has a consensus rating of “Buy” and an average price target of $13.20.
Opko Health Company Profile
OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

Receive News & Ratings for Opko Health Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Opko Health Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>